How do you manage steroid-refractory acute GVHD following allogeneic transplant?
1 Answers
Mednet Member
Medical Oncology · University of Maryland Cancer Center
The short answer is to enroll the patient in a well-designed clinical trial, if available.
If not, I would start with ruxolitinib based on the REACH2 trial (Zeiser et al., PMID 32320566) which was multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitini...